News - Events

About Us

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.
It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.

Algiax’ lead candidate AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.

Next to AP-325 Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization.

MANAGEMENT TEAM

Dr. Ingo Lehrke

CEO

Dr. Guido Koopmans

CSO

Dr. Birgit Hasse

Head of CMS and Regulator Affairs

Stefan Fischer

Finance and Transaction Advisor

Advisory Board

Dr. Jürgen Schumacher

Prof. Dr. med.
Claudia Sommer

Dr. Klaus-Dieter Langner

R & D Overview

AP-325

Algiax Pharmaceuticals has discovered AP-325, a unique proprietary small molecule drug compound, to treat neuropathic pain. AP-325 acts as a positive allosteric modulator (PAM) of the GABAA-receptor. GABAA receptor PAMs work via allosteric modulation: they do not bind at the same active site as the natural ligand Gamma-aminobutyric acid (GABAA) but affect the receptor by binding at a different site on the protein.

ThAc

Next to its AP-325 drug molecule, Algiax is investigating Thioacrylamide (ThAc) derivatives in preclinical research. ThAcs bind to the GABAA-receptor at the same binding site as AP-325 and the functional resemblance between ThAcs and AP-325 was confirmed in rodent models. Based on these and other positive results in preclinical research, Algiax is convinced that the ThAcs offer an excellent opportunity as a new treatment approach in diabetes and chronic pain.

Contact

Adress

Max-Planck-Str. 15a
40699 Erkrath
Germany

Mrs. Martina Zmugg

Team Assistant

Imprint

Information pursuant to § 5 TMG

Algiax Pharmaceuticals GmbH
Max-Planck-Str. 15a
40699 Erkrath

Commercial Register: HRB 23420
Registration Court: Wuppertal

Represented by:
Dr. Ingo Lehrke, Chief Executive Officer
Dr. Guido Koopmans, Chief Scientific Officer

VAT ID:
Sales tax identification number according to § 27a of the Sales Tax Law:
DE815282049